The Spectranetics Corporation  

(Public, NASDAQ:SPNC)   Watch this stock  
Find more results for Kimberly McIntosh
-0.11 (-0.44%)
Real-time:   10:12AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.80 - 25.13
52 week 15.52 - 31.94
Open 25.13
Vol / Avg. 24,103.00/494,826.00
Mkt cap 1.03B
P/E     -
Div/yield     -
EPS -0.12
Shares 41.58M
Beta 1.05
Inst. own 96%
Jul 24, 2014
Q2 2014 Spectranetics Corp Earnings Call - 4:30PM EDT - Add to calendar
Jul 24, 2014
Q2 2014 Spectranetics Earnings Release - 4:00PM EDT - Add to calendar
Jun 10, 2014
Spectranetics Annual Shareholder Meeting
May 28, 2014
Spectranetics at Craig-Hallum Institutional Investor Conference
May 27, 2014
Spectranetics Conference Call to discuss the merger agreement to Acquire AngioScore Inc
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -14.29% -0.23%
Operating margin -13.93% 0.25%
EBITD margin - 9.76%
Return on average assets -10.58% -0.23%
Return on average equity -12.01% -0.27%
Employees 575 -
CDP Score - -


9965 Federal Drive
United States - Map
+1-719-6338333 (Phone)
+1-877-4472022 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. Its single-use laser catheters contain up to 250 small diameter, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of lockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries; support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); therapeutic infusion system catheters for vascular delivery of drugs and diagnostic agents, and aspiration and thrombectomy catheters for the removal of thrombus (thrombus management). In July 2014, Spectranetics Corp acquired AngioScore Inc..

Officers and directors

R. John Fletcher Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Scott William Drake President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Guy A. Childs Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shahriar Matin Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
Paul Gardon Senior Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Kimberly McIntosh Bridges Senior Vice President - Sales and Marketing of Vascular Intervention
Age: 40
Bio & Compensation  - Reuters
Donna Ford-Serbu Senior Vice President - Sales and Marketing of Lead Management
Age: 45
Bio & Compensation  - Reuters
Robert Michael Fuchs Senior Vice President, Global Head - Human Resources
Age: 47
Bio & Compensation  - Reuters
Austin B. Byrd Chief Compliance Officer, Vice President
Age: 48
Bio & Compensation  - Reuters
Wade A. Bowe Vice President - Research & Development
Age: 43
Bio & Compensation  - Reuters